Alan B. Lancz & Associates, Inc. Novartis Ag Transaction History
Alan B. Lancz & Associates, Inc.
- $108 Million
- Q3 2024
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 1,918 shares of NVS stock, worth $186,199. This represents 0.2% of its overall portfolio holdings.
Number of Shares
1,918
Previous 1,918
-0.0%
Holding current value
$186,199
Previous $204,000
7.84%
% of portfolio
0.2%
Previous 0.2%
Shares
3 transactions
Others Institutions Holding NVS
# of Institutions
1,437Shares Held
131MCall Options Held
1.12MPut Options Held
1.83M-
Dodge & Cox San Francisco, CA12.2MShares$1.19 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.17 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$786 Million0.23% of portfolio
-
Morgan Stanley New York, NY6.98MShares$678 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$560 Million0.87% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $209B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...